home / stock / vtgn / vtgn news


VTGN News and Press, VistaGen Therapeutics Inc. From 02/13/20

Stock Information

Company Name: VistaGen Therapeutics Inc.
Stock Symbol: VTGN
Market: NASDAQ
Website: vistagen.com

Menu

VTGN VTGN Quote VTGN Short VTGN News VTGN Articles VTGN Message Board
Get VTGN Alerts

News, Short Squeeze, Breakout and More Instantly...

VTGN - VistaGen Therapeutics Reports Fiscal 2020 Third Quarter Financial Results and Provides CNS Pipeline Overview

SOUTH SAN FRANCISCO, Calif. , Feb. 13, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet medical need, today announced financia...

VTGN - VistaGen Therapeutics Announces Positive Preclinical Data of AV-101 Combined with Probenecid Suggesting Substantially Increased Brain Concentration Effects

SOUTH SAN FRANCISCO, Calif. , Feb. 11, 2020 /PRNewswire/ --  VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet medical need, today announced pos...

VTGN - VistaGen on go with mid-stage study of AV-101 in Parkinson's; shares up 8%

Nano cap VistaGen Therapeutics ( VTGN +7.7% ) is up on increased volume in reaction to its announcement that the FDA has signed off on its IND for a Phase 2 clinical trial evaluating NMDA glutamate receptor modulator AV-101 for the potential treatment of dyskinesia (uncontrolled muscle...

VTGN - VistaGen Therapeutics Receives FDA Clearance of IND for Phase 2 Clinical Study of AV-101 as a Potential Treatment of Dyskinesia in Parkinson's Disease Patients

SOUTH SAN FRANCISCO, Calif. , Jan. 30, 2020 /PRNewswire/ --  VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet medical need, today announced tha...

VTGN - VistaGen +19% premarket on positive AV-101 results

VistaGen Therapeutics (NASDAQ: VTGN ) is up  19%  premarket on announcing successful results from a first-step, Phase 1b clinical study with healthy U.S. military Veterans, which measured NMDAR (N-methyl-D-aspartate receptor) target engagement of VistaGen's AV-101, for potential ...

VTGN - CLNE, TRXC, TGE and ADMS among midday movers

Gainers:  Kaixin Auto (NASDAQ: KXIN ) +32% . More news on: Kaixin Auto Holdings, NantKwest, Inc., Renewable Energy Group, Inc., Stocks on the move, Read more ...

VTGN - 3 Penny Stocks To Buy For Under $1 Right Now

These Penny Stocks Can Be Bought For Under $1 Right Now; Will That Be The Case After The Holidays? One of the most important things to keep in mind about penny stocks is the fact these stocks generally trade below $5. That allows an investor to buy a large number of shares for a relatively s...

VTGN - UL, CLVS among premarket losers

Proteostasis Therapeutics (NASDAQ: PTI )  -37%  on mixed results in mid-stage CF study. More news on: Proteostasis Therapeutics, Inc., MEI Pharma, Inc., VistaGen Therapeutics, Inc., Stocks on the move, Read more ...

VTGN - Top Penny Stocks To Trade This Week? 1 Up 174% This Month

Some Of The Top Penny Stocks To Watch On Monday Penny stocks are perhaps some of the most sought after stocks in the market for those looking to make quick money. The reason behind that lies in the fact that these cheap stocks allow investors to make a substantial return even if the stock mo...

VTGN - Biotech Industry Focusing on Growing Demand for Lyophilized Injectable Drugs

December 10, 2019 Palm Beach, FL –December 10, 2019 – There are so many paths that R&D is taking in the ongoing fight against cancer. New drugs, new therapies and new techniques are developed to help researchers and practitioners across all cancer sub-markets. One su...

Previous 10 Next 10